Skeletal muscle loss during neoadjuvant chemotherapy predicts poor prognosis in patients with breast cancer

被引:21
作者
Amitani, Masatsugu [1 ]
Oba, Takaaki [1 ]
Kiyosawa, Nami [1 ]
Morikawa, Hiroki [1 ]
Chino, Tatsunori [1 ]
Soma, Ai [1 ]
Shimizu, Tadafumi [1 ]
Ohno, Koichi [1 ]
Ono, Mayu [1 ]
Ito, Tokiko [1 ]
Kanai, Toshiharu [1 ]
Maeno, Kazuma [1 ]
Ito, Ken-ichi [1 ]
机构
[1] Shinshu Univ, Sch Med, Dept Surg, Div Breast & Endocrine Surg, 3-1-1 Asahi, Matsumoto, Nagano, Japan
关键词
Skeletal muscle index; Neoadjuvant chemotherapy; Breast cancer; Disease-free survival; BODY-COMPOSITION; SARCOPENIA; SURVIVAL; MASS; TOXICITY;
D O I
10.1186/s12885-022-09443-1
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background The skeletal muscle index (SMI), which is calculated as the ratio of skeletal muscle area at the third lumbar vertebral level divided by height squared, has been considered a prognostic factor in patients with breast cancer. However, the prognostic impact of changes in SMI during treatment remains unclear. This study aimed to evaluate the influence of SMI changes in patients with breast cancer undergoing neoadjuvant chemotherapy (NAC). Methods We reviewed patients with breast cancer who underwent NAC and subsequent surgery for breast cancer between 2010 and 2017. The rate of SMI change during NAC was calculated, and the association between SMI changes and prognosis was retrospectively analyzed. Results In total, 141 patients were evaluated. 48 (34.0%), 53 (37.6%), and 40 (28.4%) patients exhibited increased (>= 3%), maintained (- 3% <, < 3%), and decreased (- 3% >=) SMI during NAC, respectively. The decreased SMI group showed significantly poorer disease-free survival than the maintained and increased SMI groups (hazard ratio [HR] 8.29, p < 0.001 for the decreased vs. increased SMI groups; HR 3.49, p < 0.001 for the decreased vs. maintained SMI groups). Moreover, decreased SMI was an independent risk factor for disease-free survival in multivariate analysis (HR 3.68, p < 0.01). Conclusions Skeletal muscle loss during NAC predicts poor prognosis. Our results underscore the importance of monitoring and maintaining skeletal muscle mass during NAC.
引用
收藏
页数:11
相关论文
共 42 条
[1]   The association of body composition parameters and adverse events in women receiving chemotherapy for early breast cancer [J].
Aleixo, G. F. P. ;
Shachar, S. S. ;
Deal, A. M. ;
Nyrop, K. A. ;
Muss, H. B. ;
Chen, Y. T. ;
Yu, H. ;
Williams, G. R. .
BREAST CANCER RESEARCH AND TREATMENT, 2020, 182 (03) :631-642
[2]   Loss of Muscle Mass During Chemotherapy Is Predictive for Poor Survival of Patients With Metastatic Colorectal Cancer [J].
Blauwhoff-Buskermolen, Susanne ;
Versteeg, Kathelijn S. ;
de van der Schueren, Marian A. E. ;
den Braver, Nicole R. ;
Berkhof, Johannes ;
Langius, Jacqueline A. E. ;
Verheul, Henk M. W. .
JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (12) :1339-+
[3]  
Caan BJ, 2018, JAMA ONCOL, V4, P798, DOI 10.1001/jamaoncol.2018.0137
[4]   Changes in neutrophil to lymphocyte ratio (NLR) during neoadjuvant treatment correlated with patients' survival [J].
Choi, Hyangsook ;
Noh, Hany ;
Cho, In-Jeong ;
Lim, Seung-Taek ;
Han, Airi .
BREAST CANCER, 2020, 27 (05) :871-879
[5]   Sarcopenia: revised European consensus on definition and diagnosis [J].
Cruz-Jentoft, Alfonso J. ;
Bahat, Gulistan ;
Bauer, Juergen ;
Boirie, Yves ;
Bruyere, Olivier ;
Cederholm, Tommy ;
Cooper, Cyrus ;
Landi, Francesco ;
Rolland, Yves ;
Sayer, Avan Aihie ;
Schneider, Stephane M. ;
Sieber, Cornel C. ;
Topinkova, Eva ;
Vandewoude, Maurits ;
Visser, Marjolein ;
Zamboni, Mauro .
AGE AND AGEING, 2019, 48 (01) :16-31
[6]   Loss of skeletal muscle during systemic chemotherapy is prognostic of poor survival in patients with foregut cancer [J].
Daly, Louise E. ;
Ni Bhuachalla, Eadaoin B. ;
Power, Derek G. ;
Cushen, Samantha J. ;
James, Karl ;
Ryan, Aoife M. .
JOURNAL OF CACHEXIA SARCOPENIA AND MUSCLE, 2018, 9 (02) :315-325
[7]   The dynamic change of neutrophil to lymphocyte ratio is predictive of pathological complete response after neoadjuvant chemotherapy in breast cancer patients [J].
Dan, Jiaqiang ;
Tan, Jinya ;
Huang, Junhua ;
Zhang, Xiaoli ;
Guo, Yao ;
Huang, Yunkun ;
Yang, Jin .
BREAST CANCER, 2020, 27 (05) :982-988
[8]   Sarcopenia associated with chemotherapy and targeted agents for cancer therapy [J].
Davis, Mellar P. ;
Panikkar, Rajiv .
ANNALS OF PALLIATIVE MEDICINE, 2019, 8 (01) :86-101
[9]   Impact of body composition on outcome in patients with early breast cancer [J].
Deluche, Elise ;
Leobon, Sophie ;
Desport, Jean Claude ;
Venat-Bouvet, Laurence ;
Usseglio, Julie ;
Tubiana-Mathieu, Nicole .
SUPPORTIVE CARE IN CANCER, 2018, 26 (03) :861-868
[10]  
Feliciano EC, 2018, P NUTR SOC, V77, P382, DOI [10.1017/s0029665118000423, 10.1017/S0029665118000423]